Form 4: ClearPoint Neuro Executive Awarded Restricted Stock Units

Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., was granted 44,280 restricted stock units on March 3, 2025, which vest over a three-year period.

Summary

• On March 3, 2025, Jeremy L. Stigall, the Chief Business Officer of ClearPoint Neuro, Inc., was granted 44,280 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of CLPT common stock per unit.
• The RSUs vest in three tranches: 20% on March 3, 2026, 40% on March 3, 2027, and the remaining 40% on March 3, 2028.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the executive's future contributions. The vesting schedule promotes long-term alignment.

Positives

• The grant of restricted stock units to a key executive aligns their interests with the long-term success of the company.
• The vesting schedule encourages continued service and contribution from the Chief Business Officer.

Future Outlook

The vesting schedule of the restricted stock units suggests an expectation of continued employment and contribution from the Chief Business Officer over the next three years.

Industry Context

Granting stock-based compensation is a common practice in the biotech and medical device industries to attract, retain, and incentivize key executives.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive incentive for the Chief Business Officer to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

ClearPoint Neuro, CLPT, restricted stock units, RSU, Jeremy L. Stigall, Chief Business Officer, executive compensation, stock options, vesting